The approval of venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine provides significant benefit for older adults with newly diagnosed acute myeloid leukemia (AML). But the therapy also comes with a specific set of challenges that clinicians are learning to tackle.
Venetoclax (Venclexta, AbbVie/Genentech) has been a “huge medical breakthrough and a much-welcomed addition” to AML therapy, one of the most aggressive leukemias, said Sara Kim, PharmD,